More about

Metabolic Dysfunction-Associated Steatotic Liver Disease

News
January 06, 2024
3 min read
Save

Gut Check-in: Healio Gastroenterology recaps trends that will shape GI practice in 2024

Gut Check-in: <i>Healio Gastroenterology</i> recaps trends that will shape GI practice in 2024

From a shift in nomenclature for steatotic liver disease to how a boom in live biotherapeutics will revamp treatment for Clostridioides difficile infection, Healio was at the forefront of gastroenterology and hepatology coverage in 2023.

News
December 18, 2023
2 min read
Save

Nomenclature change brings new opportunities for research, drug development

Nomenclature change brings new opportunities for research, drug development

The renaming of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease to metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease is a long time coming.

News
December 18, 2023
10 min read
Save

No patient left behind: MASLD rebranding provides ‘affirmative diagnosis’ without stigma

No patient left behind: MASLD rebranding provides &lsquo;affirmative diagnosis&rsquo; without stigma

In June 2023, 74% of respondents from a multinational, multisociety Delphi process agreed that the term nonalcoholic fatty liver disease was “sufficiently flawed” and 89% preferred nomenclature that described the underlying cause of disease.

News
December 08, 2023
2 min read
Save

More education needed to help PCPs ‘feel confident’ treating, managing MASLD

More education needed to help PCPs &lsquo;feel confident&rsquo; treating, managing MASLD

BOSTON — Although primary care physicians play a vital role in managing metabolic dysfunction-associated steatotic liver disease, many are not following guidance on screening, risk stratification or referrals, according to research.

News
December 07, 2023
1 min read
Save

Patients with MASLD lost less weight after bariatric surgery, study finds

Patients with MASLD lost less weight after bariatric surgery, study finds

BOSTON — Patients with metabolic dysfunction-associated steatotic liver disease who underwent bariatric surgery lost less weight over 5 years than those without MASLD, according to research presented at The Liver Meeting.

News
November 28, 2023
2 min read
Save

Aldafermin 3 mg significantly reduced Enhanced Liver Fibrosis score in MASH

Aldafermin 3 mg significantly reduced Enhanced Liver Fibrosis score in MASH

BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.

News
November 22, 2023
2 min read
Save

Up to 67% of patients achieve MASH resolution at 36 weeks with efruxifermin

Up to 67% of patients achieve MASH resolution at 36 weeks with efruxifermin

BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.

News
November 21, 2023
3 min read
Save

Retatrutide 12 mg resolved steatosis in more than 90% of patients with obesity, MASLD

Retatrutide 12 mg resolved steatosis in more than 90% of patients with obesity, MASLD

BOSTON — Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting.

News
November 21, 2023
2 min read
Save

High ultra-processed food intake linked to increased MASLD risk in adolescents, adults

High ultra-processed food intake linked to increased MASLD risk in adolescents, adults

Increased consumption of ultra-processed foods was associated with higher odds of developing metabolic dysfunction-associated steatotic liver disease in both adolescents and adults, according to research presented at The Liver Meeting.

News
November 21, 2023
2 min read
Save

Low-dose aspirin ‘potential therapeutic option’ for MASLD, markedly reduces steatosis

Low-dose aspirin &lsquo;potential therapeutic option&rsquo; for MASLD, markedly reduces steatosis

BOSTON — Low-dose aspirin significantly reduced steatosis in patients with metabolic dysfunction-associated steatotic liver disease and improved markers of liver inflammation and fibrosis, according to data presented at The Liver Meeting.

View more